Xeris Biopharma Holdings, Inc. (XERS) shareholders
Close on Nov 18, 2026Market cap $3.10BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 10,011,391 | 7.20% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XERS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,525,539 | 7.97% | $115.04M | +1,579,754 | 0.00% |
| D. E. Shaw & Co., Inc. | 7,804,758 | 4.28% | $61.81M | +15,947 | 0.03% |
| Vanguard Capital Management LLC | 7,340,229 | 4.03% | $58.13M | +359,347 | 0.00% |
| State Street Corp | 4,821,566 | 2.64% | $38.19M | +163,392 | 0.00% |
| Geode Capital Management, LLC | 4,718,183 | 2.59% | $37.37M | +427,554 | 0.00% |
| Nuveen, LLC | 4,385,141 | 2.41% | $34.73M | +1,468,543 | 0.01% |
| Rosalind Advisors, Inc. | 2,908,981 | 1.60% | $23.04M | −322,719 | 8.56% |
| Qube Research & Technologies Ltd | 2,893,749 | 1.59% | $22.92M | −1,220,676 | 0.02% |
| Vanguard Portfolio Management LLC | 2,626,208 | 1.44% | $20.80M | −39,400 | 0.00% |
| Wellington Management Group Llp | 2,365,103 | 1.30% | $18.73M | +193,749 | 0.00% |
| Morgan Stanley | 2,337,096 | 1.28% | $18.51M | −235,558 | 0.00% |
| Legal & General Group Plc | 2,012,792 | 1.10% | $15.94M | +104,503 | 0.00% |
| Armistice Capital, LLC | 1,958,702 | 1.07% | $15.51M | +48,864 | 0.19% |
| Two Sigma Investments, LP | 1,885,503 | 1.03% | $14.93M | −38,699 | 0.01% |
| Parkman Healthcare Partners LLC | 1,807,621 | 0.99% | $14.32M | +86,357 | 1.47% |
| Algert Global LLC | 1,742,942 | 0.96% | $13.80M | +585,984 | 0.16% |
| Northern Trust Corp | 1,597,749 | 0.88% | $12.65M | +153,132 | 0.00% |
| Goldman Sachs Group Inc | 1,594,072 | 0.87% | $12.63M | −19,578 | 0.00% |
| Aqr Capital Management LLC | 1,540,985 | 0.85% | $12.20M | +146,609 | 0.00% |
| Charles Schwab Investment Management Inc | 1,492,367 | 0.82% | $11.82M | +132,710 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 239 | 108M | 59.4% | 35 / 106 | 65 / 28 | 16M | 13M |
| Q1 2026 | 237 | 105M | 57.7% | 48 / 99 | 55 / 33 | 27M | 12M |
| Q4 2025 | 225 | 101M | 55.3% | 36 / 79 | 76 / 40 | 17M | 13M |
| Q3 2025 | 230 | 98M | 53.6% | 59 / 78 | 60 / 28 | 19M | 11M |
| Q2 2025 | 200 | 91M | 49.6% | 26 / 77 | 60 / 24 | 14M | 11M |
| Q1 2025 | 199 | 88M | 48.1% | 57 / 72 | 39 / 18 | 32M | 8M |
| Q4 2024 | 162 | 66M | 36.2% | 31 / 60 | 33 / 12 | 10M | 9M |
| Q3 2024 | 144 | 64M | 35.3% | 25 / 47 | 35 / 14 | 21M | 8M |
| Q2 2024 | 135 | 61M | 33.5% | 16 / 54 | 37 / 23 | 4M | 7M |
| Q1 2024 | 142 | 64M | 35.0% | 36 / 47 | 33 / 14 | 11M | 9M |
| Q4 2023 | 120 | 62M | 33.9% | 22 / 37 | 31 / 12 | 10M | 4M |
| Q3 2023 | 110 | 55M | 30.3% | 17 / 36 | 26 / 10 | 5M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
176 funds held XERS in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of XERS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,193,656 | 2.85% | $41.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,455,457 | 2.44% | $35.29M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,986,461 | 1.09% | $15.73M | 0.02% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 1,951,890 | 1.07% | $15.46M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,868,647 | 1.02% | $15.10M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,582,814 | 0.87% | $12.54M | 0.08% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 1,199,820 | 0.66% | $9.69M | 0.24% | Jul 31, 2026 |
| First Trust Small Cap Growth AlphaDEX Fund | 886,418 | 0.49% | $7.16M | 0.55% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 862,375 | 0.47% | $5.31M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 817,453 | 0.45% | $5.04M | 0.03% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 806,769 | 0.44% | $4.97M | 0.02% | May 31, 2026 |
| Nuveen Quant Small/Mid Cap Equity Fund | 797,160 | 0.44% | $6.44M | 0.24% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 753,307 | 0.41% | $5.97M | 1.39% | Jun 30, 2026 |
| Janus Henderson Small/Mid Cap Growth Alpha ETF | 644,770 | 0.35% | $5.21M | 0.50% | Jul 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 615,752 | 0.34% | $4.98M | 0.22% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John Patrick Shannon Jr | See Remarks, Director | 2,898,933 | 1.59% | Aug 21, 2026 |
| Kevin McCulloch | See Remarks | 1,584,208 | 0.87% | Nov 6, 2026 |
| Steven Pieper | See Remarks | 1,346,053 | 0.74% | Nov 4, 2026 |
| Beth Hecht | See Remarks | 1,086,130 | 0.60% | Nov 4, 2026 |
| Anh Tu Nguyen | See Remarks | 402,234 | 0.22% | Feb 25, 2026 |
| Kenneth Erland Johnson | See Remarks | 346,288 | 0.19% | Feb 3, 2025 |
| Menassie Taddese | Director | 22,365 | 0.01% | Nov 4, 2026 |
| Nerissa Kreher | Director | 33,582 | 0.02% | Jul 2, 2026 |
| John Johnson | Director | 683,083 | 0.37% | Jun 5, 2026 |
| Dawn Halkuff | Director | 124,603 | 0.07% | Jun 5, 2026 |
| James Aloysius Brady | Director | 113,359 | 0.06% | Jun 5, 2026 |
| Marla Persky | Director | 157,063 | 0.09% | Jun 5, 2026 |
| Garheng Kong | Director | 238,337 | 0.13% | Jun 5, 2026 |
| Barbara-Jean Anne Bormann-Kennedy | Director | 150,693 | 0.08% | Jun 5, 2026 |
| Jeffrey W. Sherman | Director | 224,588 | 0.12% | Aug 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kevin McCulloch See Remarks | Nov 5, 2026 | Sale(10b5-1 plan) | −25,000 | $12.49 | $312.22K | 1,559,208 |
| Steven Pieper See Remarks | Nov 2, 2026 | Sale(10b5-1 plan) | −5,000 | $10.23 | $51.17K | 1,346,053 |
| Beth Hecht See Remarks | Nov 2, 2026 | Sale(10b5-1 plan) | −25,000 | $10.23 | $255.83K | 1,086,130 |
| Kevin McCulloch See Remarks | Nov 2, 2026 | Sale(10b5-1 plan) | −15,000 | $10.23 | $153.49K | 1,584,208 |
| Menassie Taddese Director | Nov 2, 2026 | Award | +22,365 | – | – | 22,365 |
| Steven Pieper See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −5,000 | $9.41 | $47.04K | 1,351,053 |
| Kevin McCulloch See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −15,000 | $9.41 | $141.12K | 1,599,208 |
| Beth Hecht See Remarks | Oct 1, 2026 | Sale(10b5-1 plan) | −16,666 | $9.41 | $156.79K | 1,111,130 |
| Kevin McCulloch See Remarks | Sep 28, 2026 | Sale(10b5-1 plan) | −25,000 | $10.00 | $250.00K | 1,614,208 |
| Kevin McCulloch See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −15,000 | $8.49 | $127.35K | 1,639,208 |
| Beth Hecht See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −16,666 | $8.49 | $141.49K | 1,127,796 |
| Steven Pieper See Remarks | Sep 1, 2026 | Sale(10b5-1 plan) | −5,000 | $8.50 | $42.50K | 1,356,053 |
| Steven Pieper See Remarks | Aug 12, 2026 | Sale(10b5-1 plan) | −5,000 | $8.50 | $42.50K | 1,361,053 |
| Beth Hecht See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −16,666 | $8.01 | $133.49K | 1,144,462 |
| Kevin McCulloch See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −15,000 | $8.02 | $120.30K | 1,676,126 |
| Kevin McCulloch See Remarks | Aug 1, 2026 | Tax withholding | −21,918 | $8.08 | $177.10K | 1,654,208 |
| John Patrick Shannon Jr See Remarks, Director | Aug 1, 2026 | Tax withholding | −36,645 | $8.08 | $296.09K | 2,898,933 |
| Steven Pieper See Remarks | Jul 7, 2026 | Sale(10b5-1 plan) | −27,600 | $8.52 | $235.15K | 1,366,053 |
| Steven Pieper See Remarks | Jul 6, 2026 | Sale(10b5-1 plan) | −17,400 | $8.50 | $147.90K | 1,393,653 |
| Beth Hecht See Remarks | Jul 1, 2026 | Sale(10b5-1 plan) | −16,666 | $8.03 | $133.83K | 1,161,128 |
| Nerissa Kreher Director | Jul 1, 2026 | Award | +33,582 | – | – | 33,582 |
| Kevin McCulloch See Remarks | Jul 1, 2026 | Sale(10b5-1 plan) | −90,000 | $8.03 | $722.70K | 1,691,126 |
| John Johnson Director | Jun 4, 2026 | Sale(10b5-1 plan) | −15,000 | $6.09 | $91.35K | 683,083 |
| John Johnson Director | Jun 4, 2026 | Award | +24,193 | – | – | 707,276 |
| Garheng Kong Director | Jun 4, 2026 | Award | +24,193 | – | – | 238,337 |
| Barbara-Jean Anne Bormann-Kennedy Director | Jun 4, 2026 | Award | +24,193 | – | – | 150,693 |
| Barbara-Jean Anne Bormann-Kennedy Director | Jun 4, 2026 | Sale(10b5-1 plan) | −16,000 | $6.09 | $97.44K | 126,500 |
| Dawn Halkuff Director | Jun 4, 2026 | Award | +24,193 | – | – | 119,193 |
| Dawn Halkuff Director | Jun 4, 2026 | Sale(10b5-1 plan) | −20,000 | $6.09 | $121.80K | 95,000 |
| Marla Persky Director | Jun 4, 2026 | Award | +24,193 | – | – | 150,693 |
| James Aloysius Brady Director | Jun 4, 2026 | Award | +24,193 | – | – | 113,359 |
| Marla Persky Director | Jun 3, 2026 | Sale(10b5-1 plan) | −15,500 | $5.90 | $91.45K | 126,500 |
| Beth Hecht See Remarks | Jun 1, 2026 | Sale(10b5-1 plan) | −16,667 | $6.06 | $101.00K | 1,176,506 |
| Beth Hecht See Remarks | May 1, 2026 | Sale(10b5-1 plan) | −16,667 | $6.23 | $103.84K | 1,193,173 |
| Beth Hecht See Remarks | Apr 1, 2026 | Sale(10b5-1 plan) | −16,667 | $5.99 | $99.84K | 1,209,840 |
| James Aloysius Brady Director | Mar 30, 2026 | Sale(10b5-1 plan) | −10,834 | $5.54 | $60.02K | 89,166 |
| Kevin McCulloch See Remarks | Mar 12, 2026 | Option exercise | +4 | $3.94 | $16 | 1,777,725 |
| Kevin McCulloch See Remarks | Mar 12, 2026 | Option exercise | +48,894 | $4.09 | $199.98K | 1,777,721 |
| Steven Pieper See Remarks | Mar 5, 2026 | Option exercise | +27,891 | $4.09 | $114.07K | 1,394,904 |
| Steven Pieper See Remarks | Mar 5, 2026 | Option exercise | +14,036 | $5.93 | $83.23K | 1,408,940 |
| Beth Hecht See Remarks | Mar 2, 2026 | Sale(10b5-1 plan) | −100 | $7.06 | $706 | 1,226,507 |
| Beth Hecht See Remarks | Mar 2, 2026 | Sale(10b5-1 plan) | −16,567 | $6.24 | $103.38K | 1,226,607 |
| Anh Tu Nguyen See Remarks | Feb 24, 2026 | Tax withholding | −29,300 | $6.88 | $201.58K | 395,023 |
| Beth Hecht See Remarks | Feb 2, 2026 | Sale(10b5-1 plan) | −16,667 | $7.45 | $124.17K | 1,243,174 |
| John Patrick Shannon Jr See Remarks, Director | Jan 31, 2026 | Tax withholding | −118,134 | $7.36 | $869.47K | 3,157,949 |
| John Patrick Shannon Jr See Remarks, Director | Jan 31, 2026 | Tax withholding | −111,621 | $7.36 | $821.53K | 3,046,328 |
| John Patrick Shannon Jr See Remarks, Director | Jan 31, 2026 | Tax withholding | −110,750 | $7.36 | $815.12K | 2,935,578 |
| Beth Hecht See Remarks | Jan 31, 2026 | Tax withholding | −98,375 | $7.36 | $724.04K | 1,331,021 |
| Beth Hecht See Remarks | Jan 31, 2026 | Tax withholding | −24,266 | $7.36 | $178.60K | 1,259,841 |
| Beth Hecht See Remarks | Jan 31, 2026 | Tax withholding | −46,914 | $7.36 | $345.29K | 1,284,107 |
| Kevin McCulloch See Remarks | Jan 31, 2026 | Tax withholding | −27,319 | $7.36 | $201.07K | 1,727,827 |
| Kevin McCulloch See Remarks | Jan 31, 2026 | Tax withholding | −68,454 | $7.36 | $503.82K | 1,785,435 |
| Kevin McCulloch See Remarks | Jan 31, 2026 | Tax withholding | −30,289 | $7.36 | $222.93K | 1,755,146 |
| Steven Pieper See Remarks | Jan 31, 2026 | Tax withholding | −111,765 | $7.36 | $822.59K | 1,460,782 |
| Steven Pieper See Remarks | Jan 31, 2026 | Tax withholding | −66,450 | $7.36 | $489.07K | 1,394,332 |
| Steven Pieper See Remarks | Jan 31, 2026 | Tax withholding | −27,319 | $7.36 | $201.07K | 1,367,013 |
| Anh Tu Nguyen See Remarks | Jan 30, 2026 | Award | +121,293 | – | – | 424,323 |
| John Patrick Shannon Jr See Remarks, Director | Jan 30, 2026 | Award | +478,436 | – | – | 3,276,083 |
| Beth Hecht See Remarks | Jan 30, 2026 | Award | +121,293 | – | – | 1,429,396 |
| Kevin McCulloch See Remarks | Jan 30, 2026 | Award | +168,463 | – | – | 1,853,889 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Xeris Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 209,157 shares on Sep 30, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin McCulloch Officer | Nov 5, 2026 | 25,000 | $261.50K | Nov 5, 2026 | Restricted Stock Units |
| Beth Hecht Officer | Nov 2, 2026 | 75,000 | $803.25K | Nov 2, 2026 | Restricted Stock Units |
| Beth Hecht Officer | Oct 1, 2026 | 16,666 | $159.33K | Oct 1, 2026 | Restricted Stock Units |
| Kevin McCulloch Officer | Sep 28, 2026 | 70,000 | $637.00K | Sep 28, 2026 | Restricted Stock Units |
| Steven Pieper Officer | Aug 12, 2026 | 20,000 | $167.80K | Aug 12, 2026 | Restricted Stock Units |
| Steven Pieper Officer | Jul 7, 2026 | 27,600 | $231.01K | Jul 7, 2026 | Open Market Purchase |
| Steven Pieper Officer | Jul 6, 2026 | 17,400 | $144.07K | Jul 6, 2026 | Open Market Purchase |
| Kevin McCulloch Officer | Jul 1, 2026 | 120,000 | $950.40K | Jul 1, 2026 | Restricted Stock Units |
| Beth Hecht Officer | Jul 1, 2026 | 49,998 | $395.98K | Jul 1, 2026 | Restricted Stock Units |
| John Johnson Director | Jun 4, 2026 | 15,000 | $88.35K | Jun 4, 2026 | Restricted Stock Units |
| Barbara-Jean Anne Bormann-Kennedy Director | Jun 4, 2026 | 16,000 | $94.24K | Jun 4, 2026 | Restricted Stock Units |
| Dawn Halkuff Director | Jun 4, 2026 | 20,000 | $117.80K | Jun 4, 2026 | Restricted Stock Units |
| Marla Persky Director | Jun 3, 2026 | 15,500 | $93.00K | Jun 3, 2026 | Restricted Stock Units |
| James Aloysius Brady Director | Mar 30, 2026 | 10,834 | $58.50K | Mar 30, 2026 | Restricted Stock Units |
| Beth Hecht Officer | Mar 2, 2026 | 66,668 | $408.01K | Mar 2, 2026 | Restricted Stock Units |
See a number that looks wrong?